Recent advances in therapies for primary myelofibrosis
Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET) form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven by a constitutive activation of JAK2 signaling. PMF as well as secondary MF (post-ET and post-PV MF) are the most aggressive...
Main Authors: | Vainchenker, W, Yahmi, N, Havelange, V, Marty, C, Plo, I, Constantinescu, SN |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Faculty Opinions
2023
|
Similar Items
-
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis
by: Lecomte, S, et al.
Published: (2023) -
Molecular pathogenesis of myeloproliferative neoplasms: Where do we stand in 2023?
by: Havelange, V, et al.
Published: (2023) -
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice
by: Willekens, C, et al.
Published: (2023) -
Editorial: recent advances in molecular and structural endocrinology
by: De Meyts, P, et al.
Published: (2023) -
Defining disease modification in myelofibrosis in the era of targeted therapy
by: Pemmaraju, N, et al.
Published: (2022)